Sage Therapeutics (SAGE) to Release Quarterly Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGE) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Tuesday, April 29th. Analysts expect Sage Therapeutics to post earnings of ($1.00) per share and revenue of $14.12 million for the quarter.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. On average, analysts expect Sage Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sage Therapeutics Stock Performance

Shares of SAGE opened at $7.79 on Monday. The business’s 50-day moving average is $7.52 and its two-hundred day moving average is $6.76. The company has a market capitalization of $478.94 million, a P/E ratio of -1.18 and a beta of 0.48. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $14.71.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SAGE shares. Wedbush reissued a “neutral” rating and issued a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Piper Sandler dropped their price objective on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Scotiabank reduced their price target on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, February 12th. HC Wainwright restated a “neutral” rating and issued a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a report on Friday. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Sage Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.81.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.